We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Tissue Implant as Alternative to Gene Therapy

By Biotechdaily staff writers
Posted on 15 Jul 2002
Using a patient's own tissue as the site of production and delivery of precise amounts of protein is a new alternative to gene therapy and other protein injections. More...


A tiny strip of skin is taken from the patient and then genetically engineered in vitro by the introduction of specific genes via viral vectors. The small bit of tissue is transformed into a "factory”, called Biopump, which will produce a therapeutic protein for the treatment of diseases such as anemia, muscle wasting, hepatitis and other disorders. After being implanted under the skin, this modified tissue begins to deliver a measured supply of protein. Protein production can last for many months, and the therapy can be safely and immediately stopped by simply removing the implant.

"Biopump is intended as an alternative to intravenous protein injections, gene therapy and slow-release protein technologies,” said Dr. Andrew Pearlman, CEO of Medgenics, the developer of Biopump. "Injections are an inefficient way to deliver therapeutic proteins because there is an initial spike in the concentration of the proteins created at the time of intravenous injection, which can result in toxic side effects. Conversely, there is a rapid decline in protein concentration to levels that are suboptimal in therapeutic terms, and the patient must wait until the next injection until the level of therapeutic protein can be restored.”

The shape of the tissue strip is critical to the BioPump method. It has been selected to allow the tissue to live outside of the body for up to several months while it is being altered genetically. It is substantial enough to comprise a viable tissue but sufficiently thin so that all cells are close enough to the support medium to receive nutrients through diffusion. Only minimal medium is needed and there is no use of animal by-products or serum.

"This is a critical advantage over gene therapy, which is an attempt to produce a drug inside the body by injecting a virus with a desired gene that will initiate the production of a certain protein by body cells. However, it cannot be known how much protein will be produced by protein therapy or from which cells, and there is no practical way to halt gene therapy if needed,” explained Dr. Pearlman. "If you want our treatment to stop, you simply pull it out,” said Dr. Pearlman.




Related Links:
Medigenics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Manual Pipetting Aid
Pipette Controllers macro
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.